Catalent (CTLT) : Analyst Rating Update

Catalent (CTLT) : 4 brokerage houses believe that Catalent (CTLT) is a Strong Buy at current levels. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Catalent (CTLT). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 9 Wall Street Analysts endorse the stock as a Buy with a rating of 2.11.

Catalent (CTLT) : The highest short term price target forecast on Catalent (CTLT) is $31 and the lowest target price is $23. A total of 5 equity analysts are currently covering the company. The average price of all the analysts is $26.5 with a standard deviation of $2.87.

Catalent (NYSE:CTLT): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $22.70 and $22.53 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $23.03. The buying momentum continued till the end and the stock did not give up its gains. It closed at $22.82, notching a gain of 0.71% for the day. The total traded volume was 1,018,716 . The stock had closed at $22.66 on the previous day.

Also, Equity Analysts at the Wells Fargo upgrades the rating on Catalent (NYSE:CTLT). The brokerage firm has issued a Outperform rating on the shares. The shares were previously rated Market Perform. The rating by the firm was issued on June 21, 2016. The company shares have dropped -20.99% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $34.42 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $24.76 and the 200 Day Moving Average price is recorded at $25.33.

Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.